Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects.
about
Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapyEmerging drugs for the treatment of anxietyGABA and NMDA receptors in CRF neurons have opposing effects in fear acquisition and anxiety in central amygdala vs. bed nucleus of the stria terminalis.The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.Effects of corticotropin releasing factor (CRF) on sleep and temperature following predictable controllable and uncontrollable stress in miceSleep and REM sleep disturbance in the pathophysiology of PTSD: the role of extinction memory.The role of PKC signaling in CRF-induced modulation of startle.Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trialCorticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic.The CRF system, stress, depression and anxiety-insights from human genetic studies.Corticotropin-releasing factor and noradrenergic signalling exert reciprocal control over startle reactivityInteractions between corticotropin-releasing factor and the serotonin 1A receptor system on acoustic startle amplitude and prepulse inhibition of the startle response in two rat strains.Effects of corticotropin releasing factor (CRF) on sleep and body temperature following controllable footshock stress in mice.Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal modelsCRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSDCRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cuesCorticotropin releasing factor (CRF) modulates fear-induced alterations in sleep in mice.Interaction between the effects of corticotropin-releasing factor and prepulse parameters on prepulse inhibition in two inbred rat strains and the F1 generation of a cross between them.Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes.Nitric oxide as inflammatory mediator in post-traumatic stress disorder (PTSD): evidence from an animal model.Role of corticotropin releasing factor in anxiety disorders: a translational research perspectiveCorticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.Mood instability and psychosis: analyses of British national survey data.Evaluation of evidence for the psychotic subtyping of post-traumatic stress disorder.Grin1 receptor deletion within CRF neurons enhances fear memoryPost-traumatic stress disorder: emerging concepts of pharmacotherapy.The therapeutic potential of CRF1 antagonists for anxiety.The role of cortisol in PTSD among women exposed to a trauma-related stressor.Sex differences in molecular and cellular substrates of stress.Neuroendocrine and immune responses to a cognitive stress challenge in veterans with and without PTSD.Cognitive disruptions in stress-related psychiatric disorders: A role for corticotropin releasing factor (CRF).Environmental Risk and Protective Factors and Their Influence on the Emergence of PsychosisAdvances in understanding neuroendocrine alterations in PTSD and their therapeutic implications.Neuroendocrine regulation of sleep disturbances in PTSD.Sex differences in stress-related receptors: ″micro″ differences with ″macro″ implications for mood and anxiety disorders.Sex-biased stress signaling: the corticotropin-releasing factor receptor as a model.Basolateral amygdala and the regulation of fear-conditioned changes in sleep: role of corticotropin-releasing factorChildhood trauma, PTSD, and psychosis: Findings from a highly traumatized, minority sample.Modulation of stress by imidazoline binding sites: implications for psychiatric disorders.Corticotropin releasing hormone receptor 2 (CRHR-2) gene is associated with decreased risk and severity of posttraumatic stress disorder in women.
P2860
Q26860173-7337D86E-65DB-487E-A805-0DA10A6C33CBQ28083141-4EA3759D-C893-4099-926C-4D0BCAEA02FFQ30370972-F5592778-1C2F-479D-A834-F7A1BEB10C0CQ30387331-A0D3E8E7-7AE5-4333-A16F-A82BFBD12517Q30404807-CD7DC67C-9D81-4B34-B81B-ECF5436E3EAEQ30410039-906DA970-2D29-4907-99FA-AF5B85FE19F7Q30429995-57C1FC1B-2EE6-4138-A380-CC21EE0134C1Q30434663-8364C158-E307-4D26-BECA-E5FFFE7AE1EBQ30446679-F4CD8FEF-C05F-4B23-9CEA-0AF3BD2052D2Q30454302-D3CCEEB0-8261-4760-8471-9FAC2D27E224Q30456196-72631B3D-942F-4501-81CF-DA5A4D58E58DQ30459612-6618AD13-4BE2-4B83-9508-240628824652Q30462225-6F612DD1-74D9-4DD5-AF9D-FE1EFFBD84E4Q30466695-859099B9-FCA4-4E14-8ED9-CEDA8800BA0BQ30474928-6C76F0EE-DFDA-4C8D-B662-FDAE60519139Q30480573-BB2CE265-E5AA-414B-9899-5FF3BC84506FQ30481020-52AC44F3-403C-4DC1-ABC7-6CBDF8B77F28Q30481127-373BE672-2558-4641-A087-768ECED9842EQ30490796-3E05D748-2DE5-42F2-8447-D209D92A7A72Q30494165-FF7F7BD5-02E2-4EB8-9893-41DA4B9C11ECQ30498732-4C5303AF-95EB-491A-92A2-415C31D342C7Q30502566-D96B594B-280E-4164-A733-DBB6C8B94AB7Q30684656-E686D270-A155-499C-A848-E687141212ADQ34166312-1DBD9E16-3EE1-439D-8E3B-447472E6373AQ34395647-F84E7E4E-0034-4816-B944-5B76C608D917Q34981801-7AD3ECD5-ABE9-402E-A5EA-807DFF759B3BQ35814456-D6B42D4D-C85B-4EE8-8DC5-35B01D615003Q35974568-D8F6690C-6049-4A7A-B874-45636CB5177AQ36044962-EB386998-35A5-4EE5-9CB3-E0688B8A4EB5Q36108739-E2365912-F0E7-404D-8D04-312AA0BA1FF7Q36161776-43224362-5199-4DDA-B6F8-4892CFC2EEA2Q36367296-0D87299B-D0DE-4833-A72A-2903A55788A8Q36557682-F59B99EA-F20D-40EE-9719-BAA563BE4E0CQ36557686-F59E408E-7A9C-41F0-BFEB-B765B1F855C7Q36565231-E1D225B8-6024-4D6B-901D-5B9EB14B562EQ36717095-43B5FC67-BC09-4CD9-9977-FC8F43E65CA1Q36728468-DFFB42D2-4EA2-43ED-8BB2-857B7D9FD451Q37319453-7E85BA30-7896-4ED2-A2FC-1E07065A5582Q37324414-58D4B3D0-EC6E-49B5-B8C7-ED0B89D01E5CQ37373350-2D1E98BD-919B-401B-9533-DB1BAF4B7A27
P2860
Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Corticotropin-releasing factor ...... and healthy control subjects.
@ast
Corticotropin-releasing factor ...... and healthy control subjects.
@en
Corticotropin-releasing factor ...... and healthy control subjects.
@nl
type
label
Corticotropin-releasing factor ...... and healthy control subjects.
@ast
Corticotropin-releasing factor ...... and healthy control subjects.
@en
Corticotropin-releasing factor ...... and healthy control subjects.
@nl
prefLabel
Corticotropin-releasing factor ...... and healthy control subjects.
@ast
Corticotropin-releasing factor ...... and healthy control subjects.
@en
Corticotropin-releasing factor ...... and healthy control subjects.
@nl
P2093
P1476
Corticotropin-releasing factor ...... and healthy control subjects.
@en
P2093
Arleen Cerbone
Benjamin Schoenbachler
Frederic J Sautter
Garth Bissette
Gina Manguno-Mire
Janet E Johnson
Justin Wiley
Leann Myers
P304
P356
10.1016/S0006-3223(03)00571-7
P407
P577
2003-12-01T00:00:00Z